HYBIO(SZ:300199)2023-05-29 12:21Group 1: R&D Investment and Strategy - The company has adopted a hybrid strategy of generic and innovative drugs, with R&D expenses accounting for 22.53% of revenue in 2022 [1] - The company emphasizes innovation in R&D, focusing on peptide drug development, with a rich product pipeline targeting diabetes, obesity, infections, osteoporosis, and rare diseases [1] Group 2: Raw Material Business Progress - The company has over 20 years of experience in peptide raw material synthesis, establishing a strong technical barrier and high customer loyalty [2] - The raw material business has seen a compound annual growth rate (CAGR) of 48.27% over the past three years, with overseas revenue growing by 68.86% in 2022 compared to 2021 [2] - The company has secured 16 US DMFs, 5 EU DMFs, and 5 EU CEPs, facilitating international business expansion [2] Group 3: Health Industry and Product Development - The company is exploring applications of peptides in health-related scenarios such as obesity, insomnia, and high uric acid levels [2] - The HY3000 project, aimed at developing a broad-spectrum nasal spray for COVID-19, is currently in Phase IIb clinical trials [2][3] - The company is also advancing other products, including nebulizers and nasal sprays, which are in the listing application stage [3] Group 4: Financing and Expansion Plans - The company has approved a simplified procedure for issuing shares and non-public bonds to raise funds primarily for core business projects and working capital [3] - Part of the raised funds may be allocated for expanding the raw material production capacity due to rapid growth in this sector [3]